GenCell Biosystems is developing revolutionary technologies for molecular biology. GenCell Biosystems is commercializing a number of instruments based upon their innovative Composite Liquid Cell platform technology. Composite Liquid Cells (CLCs) provide an entirely new method of confining, transporting, combining, processing and analysing biological reactions to yield valuable data.
With applications including sample extraction and preparation, library preparation for next-gen sequencing, PCR genotyping, qPCR, digital PCR and proteomic assays, CLCs are versatile and can be tailored to suit virtually all protocol requirements.
Funding Rounds (1) - $3.47MUpdate
Current Team (1)Update
|Oct 20, 2014||PRNewswire All - Earnings Releases, Conference Call Schedule, Acquisitions, Drug Launches, and Initiation of Study - Research Reports on KeyCorp, Itau Unibanco, BD, Mylan and GlaxoSmithKline Editor Note: For more information about this release, please scroll to bottom.|
|Oct 14, 2014||Nasdaq - Becton, Dickinson Acquires GenCell Biosystems in Ireland - Analyst Blog|
|Jan 27, 2014||biotechnologyireland.com - GenCell Biosystems raises 3473820 in seed round|